%	O
%	O
TITLE	O

Randomised	B-Study_Type
controlled	I-Study_Type
trial	I-Study_Type
and	O
health	O
economic	O
evaluation	O
of	O
the	O
impact	O
of	O
diagnostic	O
testing	O
for	O
influenza	O
,	O
respiratory	O
syncytial	O
virus	O
and	O
Streptococcus	O
pneumoniae	O
infection	O
on	O
the	O
management	O
of	O
acute	O
admissions	O
in	O
the	O
elderly	O
and	O
high	O
-	O
risk	O
18	B-Minimum_Age_in_Study_Cohort
-	O
to	O
64	B-Maximum_Age_in_Study_Cohort
-	O
year	O
-	O
olds	O
.	O

%	O
%	O
ABSTRACT	O

Western	O
industrialised	O
nations	O
face	O
a	O
large	O
increase	O
in	O
the	O
number	O
of	O
older	O
people	O
.	O

People	O
over	O
the	O
age	O
of	O
60	O
years	O
account	O
for	O
almost	O
half	O
of	O
the	O
16	O
.	O
8	O
million	O
hospital	O
admissions	O
in	O
England	B-Study_Location
from	O
2009	O
to	O
2010	O
.	O

During	O
2009	O
-	O
10	O
,	O
respiratory	O
infections	O
accounted	O
for	O
approximately	O
1	O
in	O
30	O
hospital	O
admissions	O
and	O
1	O
in	O
20	O
of	O
the	O
51	O
.	O
5	O
million	O
bed	O
-	O
days	O
.	O
To	B-Study_Purpose
determine	I-Study_Purpose
the	I-Study_Purpose
diagnostic	I-Study_Purpose
accuracy	I-Study_Purpose
and	I-Study_Purpose
clinical	I-Study_Purpose
effectiveness	I-Study_Purpose
and	I-Study_Purpose
cost	I-Study_Purpose
-	I-Study_Purpose
effectiveness	I-Study_Purpose
of	I-Study_Purpose
rapid	I-Study_Purpose
molecular	I-Study_Purpose
and	I-Study_Purpose
near	I-Study_Purpose
-	I-Study_Purpose
patient	I-Study_Purpose
diagnostic	I-Study_Purpose
tests	I-Study_Purpose
for	I-Study_Purpose
influenza	I-Study_Purpose
,	I-Study_Purpose
respiratory	I-Study_Purpose
syncytial	I-Study_Purpose
virus	I-Study_Purpose
(	I-Study_Purpose
RSV	I-Study_Purpose
)	I-Study_Purpose
and	I-Study_Purpose
Streptococcus	I-Study_Purpose
pneumoniae	I-Study_Purpose
infections	I-Study_Purpose
in	I-Study_Purpose
comparison	I-Study_Purpose
with	I-Study_Purpose
traditional	I-Study_Purpose
laboratory	I-Study_Purpose
culture	I-Study_Purpose
.	O
We	O
carried	O
out	O
a	O
randomised	B-Study_Type
controlled	I-Study_Type
trial	I-Study_Type
(	O
RCT	B-Study_Type
)	O
to	O
evaluate	O
impact	O
on	O
prescribing	O
and	O

clinical	O
outcomes	O
of	O
point	O
-	O
of	O
-	O
care	O
tests	O
(	O
POCTs	O
)	O
for	O
influenza	O
A	O
and	O
B	O
and	O
pneumococcal	O
infection	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
tests	O
for	O
influenza	O
A	O
and	O
B	O
and	O
RSV	O
A	O
and	O
B	O
,	O
and	O
conventional	O
culture	O
for	O
these	O
pathogens	O
.	O

We	O
evaluated	O
diagnostic	O
accuracy	O
of	O
POCTs	O
for	O
influenza	O
and	O
pneumococcal	O
infection	O
,	O
RT	O
-	O
PCR	O
for	O
influenza	O
and	O
sputum	O
culture	O
for	O
S	O
.	O
pneumoniae	O
using	O
samples	O
collected	O
during	O
the	O
RCT	O
.	O

We	O
did	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
POCTs	O
for	O
influenza	O
A	O
and	O
B	O
.	O

We	O
evaluated	O
ease	O
and	O
speed	O
of	O
use	O
of	O
each	O
test	O
,	O
process	O
outcomes	O
and	O
cost	O
-	O
effectiveness	O
.	O
There	O
was	O
no	O
evidence	O
of	O
association	O
between	O
diagnostic	O
group	O
and	O
prescribing	O
or	O
clinical	O
outcomes	O
.	O

Using	O
PCR	O
as	O
'	O
gold	O
standard	O
'	O
,	O
Quidel	O
Influenza	O
Aâ€‰	O
+	O
â€‰B	O
POCT	O
detected	O
24	O
.	O
4	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
16	O
.	O
0	O
%	O
to	O
34	O
.	O
6	O
%	O
]	O
of	O
influenza	O
infections	O
(	O
specificity	O
99	O
.	O
7	O
%	O
,	O
95	O
%	O
CI	O
99	O
.	O
2	O
%	O
to	O
99	O
.	O
9	O
%	O
)	O
;	O
viral	O
culture	O
detected	O
21	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
13	O
.	O
5	O
%	O
to	O
31	O
.	O
6	O
%	O
;	O
specificity	O
99	O
.	O
8	O
%	O
,	O
95	O
%	O
CI	O
99	O
.	O
4	O
%	O
to	O
100	O
%	O
)	O
.	O

Using	O
blood	O
culture	O
as	O
'	O
gold	O
standard	O
'	O
,	O
BinaxNOW	O
pneumococcal	O
POCT	O
detected	O
57	O
.	O
1	O
%	O
(	O
95	O
%	O
CI	O
18	O
.	O
4	O
%	O
to	O
90	O
.	O
1	O
%	O
)	O
of	O
pneumococcal	O
infections	O
(	O
specificity	O
92	O
.	O
5	O
%	O
;	O
95	O
%	O
CI	O
90	O
.	O
6	O
%	O
to	O
94	O
.	O
1	O
%	O
)	O
;	O
sputum	O
culture	O
detected	O
100	O
%	O
(	O
95	O
%	O
CI	O
2	O
.	O
5	O
%	O
to	O
100	O
%	O
;	O
specificity	O
97	O
.	O
2	O
%	O
,	O
95	O
%	O
CI	O
94	O
.	O
3	O
%	O
to	O
98	O
.	O
9	O
%	O
)	O
.	O

Overall	O
,	O
pooled	O
estimates	O
of	O
sensitivity	O
and	O
specificity	O
of	O
POCTs	O
for	O
influenza	O
from	O
the	O
literature	O
were	O
74	O
%	O
(	O
95	O
%	O
CI	O
67	O
%	O
to	O
80	O
%	O
)	O
and	O
99	O
%	O
(	O
95	O
%	O
CI	O
98	O
%	O
to	O
99	O
%	O
)	O
,	O
respectively	O
.	O

Median	O
intervals	O
from	O
specimen	O
collection	O
to	O
test	O
result	O
were	O
15	O
minutes	O
[	O
interquartile	O
range	O
(	O
IQR	O
)	O
10	O
-	O
23	O
minutes	O
)	O
for	O
Quidel	O
Influenza	O
Aâ€‰	O
+	O
â€‰B	O
POCT	O
,	O
20	O
minutes	O
(	O
IQR	O
15	O
-	O
30	O
minutes	O
)	O
for	O
BinaxNOW	O
pneumococcal	O
POCT	O
,	O
50	O
.	O
8	O
hours	O
(	O
IQR	O
44	O
.	O
3	O
-	O
92	O
.	O

6	O
hours	O
)	O
for	O
semi	O
-	O
nested	O
conventional	O
PCR	O
,	O
29	O
.	O
2	O
hours	O
(	O
IQR	O
26	O
-	O
46	O
.	O
9	O
hours	O
)	O
for	O
real	O
-	O
time	O
PCR	O
,	O
629	O
.	O
6	O
hours	O
(	O
IQR	O
262	O
.	O
5	O
-	O
846	O
.	O

7	O
hours	O
)	O
for	O
culture	O
of	O
influenza	O
and	O
84	O
.	O
4	O
hours	O
(	O
IQR	O
70	O
.	O
7	O
-	O
137	O
.	O

8	O
hours	O
)	O
and	O
71	O
.	O
4	O
hours	O
(	O
IQR	O
69	O
.	O
15	O
-	O
84	O
.	O

0	O
hours	O
)	O
for	O
culture	O
of	O
S	O
.	O
pneumoniae	O
in	O
blood	O
and	O
sputum	O
,	O
respectively	O
.	O

Both	O
POCTs	O
were	O
rated	O
straightforward	O
and	O
undemanding	O
;	O
blood	O
culture	O
was	O
moderately	O
complex	O
and	O
all	O
other	O
tests	O
were	O
complex	O
.	O

Costs	O
and	O
quality	O
-	O
adjusted	O
life	O
-	O
years	O
(	O
QALYs	O
)	O
of	O
each	O
diagnostic	O
strategy	O
were	O
similar	O
.	O

Incrementally	O
,	O
PCR	O
was	O
most	O
cost	O
-	O
effective	O
(	O
78	O
.	O
3	O
%	O
probability	O
at	O
a	O
willingness	O
to	O
pay	O
of	O
Â£20	O
,	O
000	O
/	O
QALY	O
)	O
.	O

Few	O
patients	O
were	O
admitted	O
within	O
a	O
timescale	O
conducive	O
to	O
treatment	O
with	O
a	O
neuraminidase	O
inhibitor	O
according	O
to	O
National	O
Institute	O
for	O
Health	O
and	O
Care	O
Excellence	O
guidance	O
.	O
The	O
accuracy	O
study	O
was	O
limited	O
by	O
inadequate	O
gold	O
standards	O
.	O
All	O
tests	O
had	O
limitations	O
.	O

We	O
found	O
no	O
evidence	O
that	O
POCTs	O
for	O
influenza	O
or	O
S	O
.	O
pneumoniae	O
,	O
or	O
PCR	O
for	O
influenza	O
or	O
RSV	O
influenced	O
antimicrobial	O
prescribing	O
or	O
clinical	O
outcomes	O
.	O

The	O
total	O
costs	O
and	O
QALYs	O
of	O
each	O
diagnostic	O
strategy	O
were	O
similar	O
,	O
although	O
,	O
incrementally	O
,	O
PCR	O
was	O
the	O
most	O
cost	O
-	O
effective	O
strategy	O
.	O

The	O
analysis	O
does	O
not	O
support	O
routine	O
use	O
of	O
POCTs	O
for	O
either	O
influenza	O
or	O
pneumococcal	O
antigen	O
for	O
adults	O
presenting	O
with	O
acute	O
cardiopulmonary	O
conditions	O
,	O
but	O
suggests	O
that	O
conventional	O
viral	O
culture	O
for	O
clinical	O
diagnosis	O
should	O
be	O
replaced	O
by	O
PCR	O
.	O

Current	O
Controlled	O
Trials	O
ISRCTN21521552	O
.	O
This	O
project	O
was	O
funded	O
by	O
the	O
NIHR	O
Health	O
Technology	O
Assessment	O
programme	O
and	O
will	O
be	O
published	O
in	O
full	O
in	O
Health	O
Technology	O
Assessment	O
;	O
Vol	O
.	O

18	O
,	O
No	O
.	O

36	O
.	O

See	O
the	O
NIHR	O
Journals	O
Library	O
website	O
for	O
further	O
project	O
information	O
.	O

%	O
%	O
METHODS	O

We	O
conducted	O
the	O
clinical	O
trial	O
in	O
the	O
acute	O
medical	O
admissions	O
units	O
and	O
medical	O
wards	O
of	O
two	O
teaching	O
hospitals	O
(	O
Glenﬁeld	O
Hospital	O
and	O
Leicester	O
Royal	O
Inﬁrmary	O
)	O
in	O
the	O
University	O
Hospitals	O
of	O
Leicester	O
NHS	O
Trust	O
.	O

We	O
recruited	O
people	O
with	O
an	O
acute	O
exacerbation	O
of	O
chronic	O
cardiopulmonary	O
illness	O
of	O
≤	O
168	O
hours’	O

(	O
7	O
days’	O
)	O
duration	O
or	O
an	O
acute	O
cardiopulmonary	O
illness	O
of	O
≤	O
7	O
days’	O
duration	O
[	O
including	O
pneumonia	B-Pneumococcal_Disease_Type
,	O

‘inﬂuenza’	O
/	O
inﬂuenza	O
-	O
like	O
illness	O
,	O
exacerbations	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
bronchitis	O
,	O
asthma	O
,	O
congestive	O
heart	O
failure	O
or	O
cardiac	O
arrhythmia	O
]	O
,	O
who	O
satisﬁed	O
the	O
study	O
inclusion	O
and	O
exclusion	O
criteria	O
,	O
and	O
could	O
be	O
recruited	O
to	O
the	O
study	O
within	O
a	O
16	O
-	O
hour	O
period	O
of	O
initial	O
assessment	O
by	O
the	O
patient’s	O
medical	O
team	O
.	O

Participants	O
were	O
then	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
diagnostic	O
study	O
groups	O
:	O

near	O
-	O
patient	O
tests	O
for	O
pneumococcal	O
infection	O
and	O
inﬂuenza	O
;	O
(	O
2	O
)	O
rapid	O
molecular	O
tests	O
for	O
inﬂuenza	O
and	O
RSV	O
;	O
or	O
(	O
3	O
)	O
conventional	O
laboratory	O
diagnostic	O
tests	O
.	O

Identical	O
diagnostic	O
samples	O
were	O
taken	O
from	O
each	O
person	O
but	O
were	O
processed	O
differently	O
depending	O
on	O
the	O
randomisation	O
.	O

We	O
assessed	O
QoL	O
using	O
the	O
EuroQoL	O
European	O
Quality	O
of	O
Life	O
-	O
5	O
Dimensions	O
(	O
EQ	O
-	O
5D	O
)	O
tool	O
.	O

We	O
captured	O
basic	O
demographic	O
data	O
information	O
on	O
prescribed	O
medication	O
,	O
oxygen	O
and	O
intravenous	O
ﬂuids	O
,	O
investigations	O
,	O
isolation	O
status	O
,	O
complications	O
,	O
transfer	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
duration	O
of	O
stay	O
,	O
deaths	O
,	O
QoL	O
,	O
and	O
the	O
timing	O
of	O
specimen	O
collection	O
and	O
test	O
results	O
.	O

Eventually	O
,	O
all	O
tests	O
were	O
undertaken	O
on	O
all	O
specimens	O
.	O

The	O
diagnostic	O
accuracy	O
study	O
used	O
the	O
diagnostic	O
results	O
obtained	O
in	O
the	O
above	O
randomised	B-Study_Type
controlled	I-Study_Type
trial	I-Study_Type
(	O
RCT	B-Study_Type
)	O
.	O

Data	O
on	O
diagnostic	O
performance	O
of	O
the	O
various	O
tests	O
[	O
viral	O
culture	O
,	O
sputum	O
culture	O
,	O
PCR	O
,	O
Quidel	O
POCT	O
for	O
inﬂuenza	O
A	O
and	O
B	O
(	O
Quidel®	O
QuickVue	O
Inﬂuenza	O
A	O
+	O
B	O
:	O
Quidel	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
and	O
BinaxNOW®	O
(	O
Portland	O
,	O
ME	O
,	O
USA	O
)	O
POCT	O
for	O
pneumococcal	O
antigen	O
]	O
were	O
summarised	O
as	O
(	O
1	O
)	O
percentage	O
diagnostic	O
agreement	O
;	O
(	O
2	O
)	O
sensitivity	O
(	O
percentage	O
of	O
true	O
positives	O
correctly	O
identiﬁed	O
)	O
;	O
(	O
3	O
)	O
speciﬁcity	O
(	O
percentage	O
of	O
true	O
-	O
negatives	O
correctly	O
identiﬁed	O
)	O
;	O
(	O
4	O
)	O
positive	O
and	O
negative	O
predictive	O
values	O
;	O
or	O

(	O
5	O
)	O
area	O
under	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
(	O
the	O
probability	O
that	O
two	O
patients	O
,	O
one	O
diseased	O
and	O
one	O
not	O
diseased	O
,	O
would	O
be	O
both	O
correctly	O
classiﬁed	O
by	O
the	O
test	O
)	O
.	O

We	O
undertook	O
analyses	O
using	O
different	O
reference	O
standards	O
to	O
enable	O
comparison	O
between	O
the	O
results	O
from	O
our	O
study	O
and	O
those	O
found	O
in	O
the	O
literature	O
.	O

We	O
conducted	O
a	O
systematic	O
review	O
to	O
determine	O
the	O
sensitivity	O
and	O
speciﬁcity	O
of	O
POCTs	O
for	O
inﬂuenza	O
.	O

Pooled	O
sensitivities	O
and	O
speciﬁcities	O
were	O
estimated	O
using	O
a	O
bivariate	O
mixed	O
-	O
effects	O
meta	O
-	O
analysis	O
model	O
.	O

Heterogeneity	O
was	O
assessed	O
using	O
the	O
I2	O
measure	O
and	O
explored	O
using	O
subgroup	O
analyses	O
using	O
study	O
-	O
level	O
covariates	O
.	O

We	O
examined	O
the	O
speed	O
of	O
use	O
of	O
the	O
tests	O
used	O
in	O
this	O
study	O
from	O
data	O
collected	O
in	O
the	O
RCT	B-Study_Type
.	O

The	O
time	O
of	O
specimen	O
collection	O
was	O
recorded	O
in	O
the	O
case	O
report	O
forms	O
by	O
the	O
study	O
nurses	O
,	O
as	O
was	O
the	O
time	O
that	O
the	O
test	O
result	O
was	O
entered	O
into	O
the	O
continuation	O
sheets	O
in	O
the	O
patients’	O
case	O
-	O
notes	O
.	O

All	O
other	O
times	O
were	O
derived	O
from	O
the	O
intranet	O
record	O
of	O
test	O
results	O
,	O
and	O
times	O
when	O
details	O
of	O
positive	O
blood	O
culture	O
and	O
virus	O
culture	O
results	O
were	O
communicated	O
to	O
clinicians	O
.	O

We	O
assessed	O
the	O
ease	O
of	O
use	O
(	O
EoU	O
)	O
of	O
the	O
tests	O
using	O
a	O
modiﬁcation	O
of	O
the	O
US	O
Clinical	O
Laboratory	O
Improvement	O
Amendments	O
(	O
CLIA	O
)	O
Categorization	O
Criteria	O
,	O
which	O
grade	O
speciﬁc	O
laboratory	O
test	O
systems	O
,	O
assays	O
and	O
examinations	O
for	O
level	O
of	O
complexity	O
by	O
assigning	O
scores	O
of	O
1	O
,	O
2	O
or	O
3	O
for	O
each	O
of	O
seven	O
criteria	O
:	O
(	O
1	O
)	O
knowledge	O
;	O
(	O
2	O
)	O
training	O
and	O
experience	O
;	O
(	O
3	O
)	O
reagents	O
and	O
materials	O
preparation	O
;	O
(	O
4	O
)	O
characteristics	O
of	O
operational	O
steps	O
;	O
(	O
5	O
)	O
calibration	O
,	O
quality	O
control	O
and	O
proﬁciency	O
of	O
testing	O
materials	O
;	O

(	O
6	O
)	O
test	O
system	O
troubleshooting	O
and	O
equipment	O
maintenance	O
;	O
and	O
(	O
7	O
)	O
interpretation	O
and	O
judgement	O
.	O

We	O
combined	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
above	O
,	O
and	O
included	O
ﬁve	O
additional	O
criteria	O
:	O
(	O
1	O
)	O
test	O
site	O
requirements	O
;	O
(	O
2	O
)	O
equipment	O
;	O
(	O
3	O
)	O
storage	O
and	O
disposal	O
of	O
waste	O
test	O
materials	O
and	O
reagents	O
;	O
(	O
4	O
)	O
health	O
and	O
safety	O
implications	O
;	O
and	O
(	O
5	O
)	O
time	O
to	O
reporting	O
of	O
results	O
.	O

As	O
in	O
the	O
CLIA	O
system	O
,	O
a	O
score	O
of	O
1	O
indicates	O
the	O

lowest	O
level	O
of	O
complexity	O
,	O
and	O
a	O
score	O
of	O
3	O
indicates	O
the	O
highest	O
level	O
.	O

Sensitivity	O
analysis	O
was	O
also	O
undertaken	O
.	O

We	O
analysed	O
resource	O
-	O
use	O
data	O
collected	O
prospectively	O
during	O
the	O
RCT	O
while	O
the	O
patient	O
was	O
in	O
hospital	O
and	O
retrospectively	O
from	O
a	O
28	O
-	O
day	O
follow	O
-	O
up	O
.	O

An	O
incremental	O
cost	O
-	O
effectiveness	O
analysis	O
was	O
undertaken	O
,	O
with	O
cost	O
per	O
quality	O
-	O
adjusted	O
life	O
-	O
year	O
(	O
QALY	O
)	O
using	O
the	O
EQ	O
-	O
5D	O
data	O
recorded	O
during	O
the	O
RCT	B-Study_Type
.	O

Markov	O
chain	O
Monte	O
Carlo	O
methods	O
were	O
used	O
to	O
estimate	O
the	O
uncertainty	O
surrounding	O
outcome	O
measures	O
,	O
and	O
calculate	O
the	O
probability	O
of	O
strategies	O
being	O
cost	O
-	O
effective	O
at	O
willingness	O
-	O
to	O
-	O
pay	O
thresholds	O
of	O
£20	O
,	O
000	O
and	O

£30	O
,	O
000	O
per	O
QALY	O
,	O
together	O
with	O
the	O
probability	O
of	O
error	O
for	O
any	O
strategy	O
adopted	O
.	O

Literature	O
searches	O

On	O
-	O
line	O
searches	O
were	O
made	O
on	O
MEDLINE	O
/	O
PubMed	O
on	O
28	O
April	O
2011	O
and	O
on	O
the	O
Bioscience	O
Information	O
Service	O
(	O
BIOSIS	O
)	O
and	O
The	O
Cochrane	O
library	O
on	O
27	O
May	O
2011	O
for	O
publications	O
on	O
inﬂuenza	O
POCT	O
diagnostic	O
accuracy	O
studies	O
between	O
1991	O
and	O
2011	O
(	O
inclusive	O
)	O
that	O
met	O
the	O
following	O
ﬁve	O
criteria	O
:	O

Articles	O
written	O
in	O
English	O
.	O

Commercially	O
available	O
test	O
kits	O
.	O

Testing	O
done	O
in	O
human	O
seasonal	O
and	O
pandemic	O
inﬂuenza	O
.	O

Sensitivity	O
results	O
with	O
speciﬁc	O
numerators	O
and	O
denominators	O
.	O

We	O
had	O
authorised	O
journal	O
access	O
.	O

Medical	O
subject	O
heading	O
(	O
MeSH	O
)	O
search	O
phrases	O
included	O
:	O

“QuickVue	O
test	O
inﬂuenza”	O
.	O

“Rapid	O
inﬂuenza	O
test”	O
.	O

“Rapid	O
antigen	O
test	O
inﬂuenza”	O
.	O

“POCT	O
inﬂuenza”	O
.	O

“Immunochromatographic	O
test	O
inﬂuenza”	O
.	O

“Bedside	O
test	O
inﬂuenza”	O
.	O

shows	O
a	O
ﬂow	O
diagram	O
of	O
the	O
manuscript	O
screening	O
process	O
,	O
taken	O
from	O
the	O
Preferred	O
Reporting	O
Items	O
for	O
Systematic	O
Reviews	O
and	O
Meta	O
-	O
Analyses	O
(	O
PRISMA	O
)	O
guideline	O
on	O
systematic	O
reviews	O
.	O

Manuscript	O
scoring	O

The	O
QUADAS	O
tool	O
is	O
an	O
evidence	O
-	O
based	O
scheme	O
for	O
the	O
determination	O
of	O
the	O
quality	O
of	O
both	O
the	O
methodology	O
and	O
the	O
reporting	O
of	O
ﬁndings	O
when	O
doing	O
systematic	O
reviews	O
.	O

It	O
consists	O
of	O
14	O
questions	O
called	O
‘items’	O
about	O
the	O
study	O
patients	O
,	O
selection	O
criteria	O
,	O
testing	O
standards	O
,	O
results	O
and	O
clinical	O
data	O
that	O
were	O
answered	O
with	O
a	O
‘yes	O
,	O
’	O
‘no’	O
or	O
‘unclear	O
.	O
’	O

FIGURE	O
7	O
The	O
manuscript	O
screening	O
process	O
.	O

a	O
.	O

Partial	O
data	O
from	O
three	O
publications	O
.	O

The	O
STARD	O
initiative	O
was	O
another	O
evidence	O
-	O
based	O
tool	O
used	O
to	O
assess	O
the	O
accuracy	O
,	O
completeness	O
,	O
and	O
risk	O
of	O
bias	O
in	O
the	O
systematic	O
review	O
of	O
diagnostic	O
accuracy	O
studies	O
.	O

The	O
STARD	O
checklist	O
consists	O
of	O
25	O
questions	O
pertaining	O
to	O
a	O
study’s	O
title	O
,	O
introduction	O
,	O
methodology	O
,	O
results	O
and	O
discussion	O
sections	O
;	O
the	O
more	O
of	O
the	O

25	O
items	O
that	O
are	O
identiﬁed	O
or	O
described	O
in	O
the	O
report	O
,	O
the	O
more	O
favourable	O
the	O
outcome	O
.	O

Data	O
analysis	O

For	O
those	O
studies	O
that	O
reported	O
a	O
full	O
2	O
×	O
2	O
table	O
,	O
i	O
.	O
e	O
.	O
numbers	O
of	O
true	O
-	O
positives	O
,	O
false	O
-	O
positives	O
,	O
false	O
-	O
negatives	O
and	O
true	O
-	O
negatives	O
,	O
or	O
for	O
which	O
these	O
could	O
be	O
calculated	O
,	O
pooled	O
sensitivity	O
and	O

speciﬁcities	O
were	O
estimated	O
using	O
a	O
bivariate	O
mixed	O
-	O
effects	O
meta	O
-	O
analysis	O
model	O
.	O
As	O
well	O
as	O
summarising	O
the	O
overall	O
diagnostic	O
measures	O
a	O
hierarchical	O
summary	O
ROC	O
curve	O
was	O
also	O
estimated	O
using	O
the	O
derived	O
logit	O
estimates	O
of	O
sensitivity	O
,	O
speciﬁcity	O
and	O
their	O
respective	O
variances	O
.	O
Heterogeneity	O
was	O
assessed	O
using	O
the	O
I2	O
measure	O
and	O
explored	O
using	O
subgroup	O
analyses	O
using	O
study	O
-	O
level	O
covariates	O
.	O
A	O
number	O
of	O
studies	O
reported	O
only	O
estimates	O
of	O
sensitivity	O
,	O
and	O
in	O
order	O
to	O
explore	O
whether	O
there	O
was	O
a	O
selection	O

effect	O
between	O
those	O
studies	O
that	O
reported	O
both	O
sensitivity	O
and	O
speciﬁcity	O
,	O
and	O
those	O
that	O
reported	O
only	O
sensitivity	O
,	O

a	O
sensitivity	O
analysis	O
was	O
undertaken	O
in	O
which	O
the	O
sensitivities	O
were	O
pooled	O
separately	O
for	O
the	O
two	O
groups	O
of	O
studies	O
using	O
a	O
standard	O
random	O
-	O
effects	O
meta	O
-	O
analysis	O
model	O
on	O
the	O
logit	O
scale	O
,	O
and	O
the	O
pooled	O
estimates	O
compared	O
.	O

Resource	O
use	O
data	O
and	O
unit	O
costs	O

displays	O
the	O
unit	O
costs	O
,	O
derived	O
from	O
a	O
variety	O
of	O
sources	O
,	O
for	O
the	O
various	O
major	O
resource	O
use	O
components	O
identiﬁed	O
in	O
3WS	O
.	O

As	O
well	O
as	O
the	O
unit	O
costs	O
in	O
,	O
all	O
drugs	O
prescribed	O
in	O
the	O
index	O
admission	O
,	O
and	O
subsequently	O
associated	O
with	O
the	O
index	O
admission	O
,	O
were	O
costed	O
using	O
the	O
British	O
National	O
Formulary	O
(	O
BNF	O
)	O
.	O
The	O
price	O
year	O
adopted	O
was	O
2007–8	O
,	O
i	O
.	O
e	O
.	O
the	O
ﬁnal	O
year	O
of	O
the	O
study	O
,	O
and	O
those	O
unit	O
prices	O
that	O
were	O
not	O
in	O
this	O
year	O
were	O
adjusted	O
accordingly	O
using	O
the	O
Hospital	O
and	O
Community	O
Health	O
Services	O
(	O
HCHS	O
)	O
Pay	O
and	O
Price	O
Index	O
.	O
No	O
discounting	O
of	O
either	O
costs	O
or	O
QALYs	O
was	O
applied	O
to	O
the	O

cost	O
-	O
effectiveness	O
analyses	O
,	O
as	O
the	O
time	O
horizon	O
over	O
which	O
patients	O
were	O
followed	O
was	O
28	O
days	O
.	O

As	O
well	O
as	O
the	O
average	O
total	O
cost	O
per	O
patient	O
for	O
each	O
of	O
the	O
diagnostic	O
strategies	O
,	O
the	O
main	O
cost	O
components	O
,	O
namely	O
hospital	O
stay	O
(	O
both	O
non	O
-	O
ITU	O
and	O
ITU	O
)	O
,	O
index	O
test	O
costs	O
(	O
including	O
stafﬁng	O
and	O
materials	O
)	O
,	O
complications	O
[	O
myocardial	O
infarction	O
,	O
stroke	O
,	O
urinary	O
tract	O
infection	O
,	O
wound	O
infection	O
,	O
MRSA	O
/	O
Clostridium	O
difficile	O
)	O
,	O

post	O
-	O
discharge	O
visits	O
(	O
GP	O
/	O
nurse	O
visits	O
)	O
and	O
A	O
&	O
E	O
attendance	O
]	O
,	O
additional	O
investigations	O
(	O
electrocardiography	O
,	O

full	O
blood	O
count	O
,	O
blood	O
gases	O
,	O
blood	O
biochemistry	O
,	O
oxygen	O
levels	O
,	O
ward	O
-	O
based	O
urine	O
analysis	O
and	O
chest	O
radiography	O
)	O
and	O
antibiotic	O
prescribing	O
(	O
both	O
for	O
the	O
index	O
admission	O
and	O
post	O
discharge	O
)	O
were	O
also	O
reported	O
in	O
terms	O
of	O
means	O
and	O
SDs	O
.	O

Owing	O
to	O
the	O
relatively	O
large	O
sample	O
size	O
,	O
both	O
cost	O
components	O
and	O
mean	O
resource	O
were	O
formally	O
compared	O
between	O
the	O
diagnostic	O
strategies	O
using	O
parametric	O
methods	O
–	O
one	O
-	O
way	O
ANOVA	O
or	O
Fisher’s	O
exact	O
test	O
as	O
appropriate	O
.	O

TABLE	O
32	O
Unit	O
costs	O
for	O
the	O
various	O
resources	O
collected	O

Ward	O
276	O
.	O
21	O
HRG	O
code	O
and	O
DH	O
Reference	O
Costs	O

ITU	O
1410	O
.	O
54	O
HRG	O
code	O
and	O
DH	O
Reference	O
Costs	O

Oxygen	O
therapy	O
212	O
.	O
00	O
HRG	O
code	O
and	O
DH	O
Reference	O
Costs	O

Ward	O
-	O
based	O
CPAP	O
219	O
.	O
75	O
HRG	O
code	O
and	O
DH	O
Reference	O
Costs	O

Quidel	O
15	O
.	O
83	O
UHL	O
NHS	O
Trust	O

Binax	O
25	O
.	O
56	O
UHL	O
NHS	O
Trust	O

Blood	O
culture	O
46	O
.	O
00	O
UHL	O
NHS	O
Trust	O

Viral	O
culture	O
48	O
.	O
00	O
UHL	O
NHS	O
Trust	O

Sputum	O
culture	O
38	O
.	O
00	O
UHL	O
NHS	O
Trust	O

PCR	O
48	O
.	O
00	O
UHL	O
NHS	O
Trust	O

Myocardial	O
infarction	O
1138	O
.	O
64	O
Bravo	O
-	O
Vergel	O
et	O
al	O
.	O

Stroke	O
790	O
.	O
03	O
Bravo	O
-	O
Vergel	O
et	O
al	O
.	O

Urinary	O
tract	O
infection	O
32	O
.	O
08	O
Turner	O
et	O
al	O
.	O

Wound	O
infection	O
148	O
.	O
00	O
DH	O
NHS	O
Reference	O
Costs	O

MRSA	O
/	O
C	O
.	O

difficile	O
688	O
.	O
00	O
DH	O
NHS	O
Reference	O
Costs	O

GP	O
:	O
surgery	O
36	O
.	O
00	O
PSSRU	O

GP	O
:	O
home	O
58	O
.	O
00	O
PSSRU	O

Practice	O
nurse	O
11	O
.	O
00	O
PSSRU	O

District	O
nurse	O
26	O
.	O
00	O
PSSRU	O

Home	O
-	O
care	O
worker	O
39	O
.	O
00	O
PSSRU	O

A	O
&	O
E	O
attendance	O
111	O
.	O
00	O
PSSRU	O

Electrocardiography	O
33	O
.	O
45	O
DH	O
NHS	O
Reference	O
Costs	O

Full	O
blood	O
count	O
2	O
.	O
99	O
DH	O
NHS	O
Reference	O
Costs	O

Blood	O
gases	O
2	O
.	O
99	O
DH	O
NHS	O
Reference	O
Costs	O

Oxygen	O
levels	O
2	O
.	O
99	O
DH	O
NHS	O
Reference	O
Costs	O

Blood	O
biochemistry	O
1	O
.	O
34	O
DH	O
NHS	O
Reference	O
Costs	O

Ward	O
urine	O
analysis	O
9	O
.	O
15	O
DH	O
NHS	O
Reference	O
Costs	O

Chest	O
radiography	O
16	O
.	O
00	O
DH	O
NHS	O
Reference	O
Costs	O

Statistical	O
model	O

Model	O
A	O

In	O
order	O
to	O
simultaneously	O
allow	O
for	O
the	O
potential	O
for	O
correlation	O
between	O
cost	O
and	O
outcome	O
a	O
bivariate	O
model	O
was	O
assumed	O
for	O
the	O
two	O
outcomes	O
.	O
Thus	O
,	O
if	O
y1ij	O
and	O
y2ij	O
represented	O
the	O
total	O
costs	O
and	O
QALYs	O
for	O
the	O
ith	O
patient	O
in	O
the	O
jth	O
group	O
,	O
respectively	O
,	O
these	O
were	O
then	O
assumed	O
to	O
come	O
from	O
a	O
bivariate	O
normal	O
distribution	O
(	O
model	O
A	O
)	O
,	O
such	O
that	O
:	O

y1ij	O
∼N	O
μ1j	O
,	O
Σj	O
ð1Þ	O

where	O
μ1j	O
and	O
μ2j	O
are	O
the	O
mean	O
total	O
costs	O
and	O
mean	O
QALYs	O
for	O
the	O
jth	O
randomisation	O
group	O
respectively	O
,	O
and	O
Σj	O
is	O
the	O
associated	O
covariance	O
matrix	O
.	O

Adopting	O
a	O
Bayesian	O
approach	O
to	O
estimating	O
the	O
unknown	O
parameters	O
of	O
model	O

Σ−1	O
1	O

2	O
−1	O

∼	O
WishartðA	O
,	O
kÞ	O
ð2Þ	O

A	O
10	O
,	O
000	O
0	O

0	O
0	O
.	O

01	O

l	O
ð3Þ	O

ﬁ	O

Estimation	O
of	O
model	O
parameters	O
and	O
software	O

The	O
results	O
were	O
reported	O
as	O
posterior	O
means	O
and	O
95	O
%	O
CrIs	O
,	O
which	O
are	O
analogous	O
to	O
CIs	O
.	O

Primary	O
results	O
are	O
based	O
on	O
a	O
‘burn	O
-	O
in’	O
of	O
20	O
,	O
000	O
iterations	O
followed	O
by	O
a	O
further	O
sample	O
of	O
50	O
,	O
000	O
iterations	O
.	O

Further	O
sensitivity	O
analyses	O
were	O
conducted	O
to	O
assess	O
both	O
convergence	O
/	O
mixing	O
of	O
the	O
sampling	O
algorithm	O
and	O
inﬂuence	O
of	O
prior	O
distributions	O
,	O
which	O
were	O
all	O
chosen	O
to	O
be	O
non	O
-	O
informative	O
.	O

Appendix	O
8	O
displays	O
a	O
sample	O
of	O
the	O
WinBUGS	O
code	O
used	O
for	O
model	O
A	O
.	O

The	O
model	O
parameters	O
were	O
estimated	O
in	O
WinBUGS	O
1	O
.	O
4	O
.	O
3	O
,	O
and	O
further	O
post	O
-	O
estimation	O
processing	O
of	O
the	O
samples	O
was	O
undertaken	O
in	O
R	O
.	O

Missing	O
data	O

There	O
were	O
missing	O
values	O
for	O
both	O
total	O
costs	O
and	O
QALYs	O
for	O
a	O
number	O
of	O
patients	O
(	O
costs	O
–	O
traditional	O
8	O
.	O
4	O
%	O
,	O
POCT	O
8	O
.	O
6	O
%	O
and	O
PCR	O
8	O
.	O
4	O
%	O
;	O
QALYs	O
–	O
traditional	O
51	O
.	O
1	O
%	O
,	O
POCT	O
44	O
.	O
0	O
%	O
and	O
PCR	O
48	O
.	O
1	O
%	O
)	O
and	O
these	O
were	O
treated	O
as	O
unknown	O
parameters	O
in	O
the	O
estimation	O
of	O
model	O
A	O
,	O
and	O
hence	O
at	O
each	O
iteration	O
values	O
were	O
sampled	O
from	O
their	O
corresponding	O
posterior	O
predictive	O
distribution	O
,	O
i	O
.	O
e	O
.	O
conditional	O
upon	O
both	O
the	O
data	O
and	O
the	O
model	O
parameters	O
,	O
in	O
a	O
manner	O
similar	O
to	O
multiple	O
imputation	O
.	O
Thus	O
,	O
appropriate	O
allowance	O

for	O
all	O
uncertainty	O
in	O
the	O
MCMC	O
estimated	O
mean	O
total	O
costs	O
and	O
QALYs	O
has	O
been	O
made	O
.	O

Assessment	O
of	O
cost	O
-	O
effectiveness	O

Having	O
estimated	O
the	O
mean	O
effects	O
,	O
i	O
.	O
e	O
.	O

QALYs	O
and	O
total	O
costs	O
per	O
patient	O
,	O
and	O
after	O
allowing	O
for	O
the	O
imputation	O
of	O
missing	O
data	O
,	O
the	O
posterior	O
probability	O
of	O
each	O
diagnostic	O
strategy	O
being	O
the	O
least	O
costly	O
and	O
also	O
having	O
the	O
highest	O
gain	O
in	O
QALYs	O
was	O
estimated	O
from	O
the	O
MCMC	O
samples	O
,	O
i	O
.	O
e	O
.	O
at	O
each	O
iteration	O
the	O
strategies	O
were	O
ranked	O
and	O
the	O
probability	O
of	O
each	O
strategy	O
being	O
ranked	O
ﬁrst	O
(	O
for	O
QALYs	O
)	O
and	O
third	O
(	O
for	O
costs	O
)	O
was	O
calculated	O
as	O
the	O
proportion	O
of	O
iterations	O
for	O
which	O
this	O
was	O
the	O
case	O
.	O

An	O
incremental	O

cost	O
-	O
effectiveness	O
analysis	O
was	O
then	O
undertaken	O
in	O
which	O
the	O
three	O
diagnostic	O
strategies	O
were	O
ﬁrst	O
ranked	O
in	O
terms	O
of	O
ascending	O
cost	O
,	O
and	O
then	O
any	O
strategies	O
which	O
were	O
dominated	O
,	O
i	O
.	O
e	O
.	O
for	O
which	O
there	O
was	O
another	O
strategy	O
which	O
produced	O
a	O
greater	O
QALY	O
gain	O
at	O
lower	O
cost	O
,	O
or	O
extendedly	O
dominated	O
,	O
i	O
.	O
e	O
.	O
for	O
which	O
there	O
was	O
another	O
combination	O
of	O
strategies	O
which	O
produced	O
the	O
same	O
QALY	O
gain	O
at	O
lower	O
cost	O
,	O
were	O
excluded	O
from	O
the	O
incremental	O
analysis	O
.	O

For	O
the	O
two	O
or	O
three	O
strategies	O
that	O
remain	O
,	O
cost	O
-	O
effectiveness	O
was	O
then	O
assessed	O
by	O
calculating	O
the	O
appropriate	O
incremental	O
cost	O
-	O
effectiveness	O
ratios	O
(	O
ICERs	O
)	O
to	O
obtain	O
an	O
estimate	O
of	O
cost	O
per	O
additional	O
QALY	O
.	O

Thus	O
,	O
for	O
two	O
strategies	O
,	O
j	O
and	O
k	O
,	O
the	O
ICER	O
is	O
obtained	O
by	O
:	O

ICER	O
μ1j	O
−	O
μ1k	O
μ2j	O
−	O
μ2k	O

ð4Þ	O

where	O
μ¯	O
1j	O
and	O
μ¯	O
2j	O
are	O
obtained	O
by	O
averaging	O
over	O
the	O
MCMC	O
samples	O
in	O
R	O
outside	O
WinBUGS	O
.	O

The	O
probability	O
of	O
cost	O
-	O
effectiveness	O
at	O
willingness	O
-	O
to	O
-	O
pay	O
thresholds	O
,	O
λ	O
,	O
of	O
£20	O
,	O
000	O
per	O
QALY	O
and	O
£30	O
,	O
000	O
per	O
QALY	O
,	O
the	O
currently	O
accepted	O
thresholds	O
for	O
NICE	O
,	O
were	O
estimated	O
as	O
the	O
proportion	O
of	O
MCMC	O
samples	O
for	O
which	O
the	O
corresponding	O
monetary	O
net	O
-	O
beneﬁt	O
(	O
NB	O
)	O
function	O
was	O
positive	O
.	O

Thus	O
,	O
for	O
strategy	O
j	O
the	O
NB	O
function	O
is	O
given	O
by	O

NB	O
¼	O
μ2jλ	O
−	O
μ1j	O
ð5Þ	O

In	O
addition	O
,	O
the	O
probability	O
of	O
error	O
for	O
any	O
strategy	O
deemed	O
to	O
be	O
cost	O
-	O
effective	O
was	O
also	O
estimated	O
,	O

i	O
.	O
e	O
.	O
the	O
probability	O
that	O
by	O
adopting	O
that	O
strategy	O
an	O
incorrect	O
adoption	O
decision	O
had	O
been	O
made	O
.	O

For	O
the	O
incremental	O
cost	O
per	O
conﬁrmed	O
case	O
of	O
inﬂuenza	O
analysis	O
,	O
the	O
strategies	O
were	O
again	O
ranked	O
in	O
terms	O
of	O
ascending	O
average	O
total	O
cost	O
per	O
patient	O
,	O
and	O
the	O
mean	O
total	O
cost	O
per	O
case	O
,	O
conﬁrmed	O
using	O
serology	O
(	O
see	O
)	O
,	O
estimated	O
.	O

Sensitivity	O
analyses	O

A	O
series	O
of	O
one	O
-	O
way	O
sensitivity	O
analyses	O
were	O
undertaken	O
to	O
examine	O
whether	O
the	O
MCMC	O
methods	O

(	O
i	O
.	O
e	O
.	O
initial	O
settings	O
of	O
burn	O
-	O
in	O
,	O
sample	O
length	O
and	O
starting	O
values	O
)	O
,	O
prior	O
distributions	O
,	O
statistical	O
model	O
or	O
price	O
of	O
PCR	O
or	O
POCT	O
had	O
an	O
impact	O
on	O
the	O
mean	O
costs	O
and	O
QALYs	O
,	O
i	O
.	O
e	O
.	O
μ1j	O
and	O
μ2j	O
,	O
and	O
therefore	O
on	O
the	O
incremental	O
cost	O
-	O
effectiveness	O
analysis	O
.	O

Markov	O
chain	O
Monte	O
Carlo	O
methods	O

To	O
assess	O
evidence	O
of	O
non	O
-	O
convergence	O
,	O
the	O
history	O
trace	O
plots	O
,	O
i	O
.	O
e	O
.	O
the	O
sampled	O
values	O
at	O
each	O
iteration	O
plotted	O
against	O
iteration	O
number	O
,	O
were	O
examined	O
for	O
systematic	O
movement	O
in	O
the	O
chain	O
and	O
therefore	O
evidence	O
of	O
non	O
-	O
convergence	O
.	O

In	O
addition	O
,	O
the	O
auto	O
-	O
correlation	O
functions	O
/	O
plots	O
were	O
examined	O
to	O
identify	O
poor	O
mixing	O
of	O
the	O
MCMC	O
sampler	O
,	O
i	O
.	O
e	O
.	O
that	O
successive	O
sampled	O
values	O
were	O
not	O
entirely	O
random	O
,	O
and	O
therefore	O
a	O
longer	O
sample	O
length	O
would	O
be	O
required	O
.	O

To	O
assess	O
the	O
sensitivity	O
of	O
the	O
cost	O
-	O
effectiveness	O
results	O
to	O
the	O
length	O
of	O
burn	O
-	O
in	O
,	O
length	O
of	O
sample	O
,	O
initial	O
starting	O
values	O
and	O
prior	O
distributions	O
in	O
using	O
MCMC	O
methods	O
to	O
estimate	O
mean	O
costs	O
and	O
QALYs	O
,	O
a	O
number	O
of	O
one	O
-	O
way	O
sensitivity	O
analyses	O
were	O
undertaken	O
.	O

Speciﬁcally	O
,	O
two	O
additional	O
sets	O
of	O
length	O
of	O
burn	O
-	O
in	O
/	O
sample	O
were	O
used	O
:	O
10	O
,	O
000	O
/	O
20	O
,	O
000	O
and	O
50	O
,	O
000	O
/	O
100	O
,	O
000	O
compared	O
with	O
the	O
base	O
-	O
case	O
analysis	O
,	O

which	O
used	O
20	O
,	O
000	O
/	O
50	O
,	O
000	O
.	O

Alternative	O
prior	O
distributions	O
for	O
μ1j	O
and	O
μ2j	O
were	O
also	O
used	O
,	O
i	O
.	O
e	O
.	O

N	O
(	O
0	O
,	O
105	O
)	O
and	O
N	O

(	O
0	O
,	O
1	O
)	O
,	O
respectively	O
,	O
compared	O
with	O
N	O
(	O
0	O
,	O
108	O
)	O
and	O
N	O
(	O
0	O
,	O
10–2	O
)	O
in	O
the	O
base	O
case	O
,	O
and	O
A	O
was	O
set	O
such	O
that	O
:	O

A	O
1000	O
0	O
.	O
5	O
6	O

0	O
.	O
5	O
0	O
.	O
1	O

Finally	O
,	O
two	O
additional	O
chains	O
,	O
i	O
.	O
e	O
.	O
runs	O
of	O
the	O
MCMC	O
sampler	O
,	O
were	O
used	O
with	O
qualitatively	O
very	O
different	O
initial	O
starting	O
values	O
to	O
those	O
used	O
in	O
the	O
base	O
case	O
,	O
and	O
Brooks–Gelman–Rubin	O
plots	O
were	O
explored	O
,	O
as	O
well	O
as	O
the	O
separate	O
summary	O
statistics	O
for	O
μ1j	O
and	O
μ2j	O
,	O
to	O
identify	O
evidence	O
that	O
the	O
chains	O
did	O
not	O
produce	O
qualitatively	O
similar	O
results	O
.	O

The	O
Brooks–Gelman–Rubin	O
plots	O
compare	O
the	O
width	O
of	O
80	O
%	O
CrIs	O
of	O
the	O
pooled	O
chains	O
with	O
the	O
average	O
width	O
of	O
80	O
%	O
CrIs	O
across	O
chains	O
–	O
the	O
two	O
should	O
be	O
the	O
same	O
unless	O
there	O
is	O
evidence	O
of	O
non	O
-	O
convergence	O
.	O

This	O
also	O
gives	O
an	O
informal	O
way	O
in	O
which	O
to	O
check	O
whether	O
a	O
longer	O
period	O
of	O
burn	O
-	O
in	O
is	O
required	O
.	O

Model	O
B	O

Model	O
A	O

ηj	O

y	O
∼	O
Gammaðη	O
,	O
λ	O
Þ	O
λ	O
¼	O

ð7Þ	O

1ij	O

j	O
i	O
i	O
ϕi	O

logitðy2ijÞ∼Nðμ2	O
,	O
σ2Þ	O
where	O
ϕi	O
¼	O
μ1	O
þ	O
β	O
ðy2ij−μ2	O
Þ	O
ð8Þ	O

The	O
unknown	O
parameters	O
in	O
(	O
7	O
)	O
and	O
(	O
8	O
)	O
are	O
then	O
given	O
plausible	O
yet	O
vague	O
or	O
non	O
-	O
informative	O
prior	O
and	O
in	O

between	O

directly	O

QALYs	O
on	O

Price	O
reductions	O
for	O
polymerase	O
chain	O
reaction	O
and	O
point	O
-	O
of	O
-	O
care	O
test	O

To	O
assess	O
the	O
impact	O
of	O
price	O
of	O
the	O
index	O
test	O
in	O
the	O
different	O
diagnostic	O
strategies	O
,	O
further	O

cost	O
-	O
effectiveness	O
analyses	O
were	O
undertaken	O
in	O
which	O
either	O
the	O
price	O
of	O
PCR	O
or	O
POCT	O
,	O
as	O
these	O
are	O
evolving	O
technologies	O
,	O
was	O
reduced	O
by	O
either	O
20	O
%	O
or	O
50	O
%	O
.	O

